Chapter 4. Development of Agents that Selectively Disrupt Tumor Vasculature: A Historical Perspective

  1. Dietmar W. Siemann3,4
  1. David J. Chaplin1 and
  2. Sally A. Hill2

Published Online: 31 MAY 2006

DOI: 10.1002/0470035439.ch4

Vascular-Targeted Therapies in Oncology

Vascular-Targeted Therapies in Oncology

How to Cite

Chaplin, D. J. and Hill, S. A. (2006) Development of Agents that Selectively Disrupt Tumor Vasculature: A Historical Perspective, in Vascular-Targeted Therapies in Oncology (ed D. W. Siemann), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470035439.ch4

Editor Information

  1. 3

    Shands Cancer Center, University of Florida, Gainsville, Florida, USA

  2. 4

    Research Department of Radiation Oncology, University of Florida, 2000 RW Archer Road, Gainsville, FL 32610, USA

Author Information

  1. 1

    Research and Development, Oxigene Inc., 230 3rd Avenue, Waltham, MA 02451, USA

  2. 2

    Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, UK

Publication History

  1. Published Online: 31 MAY 2006
  2. Published Print: 10 MAR 2006

ISBN Information

Print ISBN: 9780470012949

Online ISBN: 9780470035436

SEARCH

Keywords:

  • antiangiogenic therapies;
  • small-molecule-based VDAs;
  • vascular occlusion on tumor cell survival;
  • VDA therapeutics;
  • VDA - flavone acetic acid (FAA);
  • N-cadherin antagonists;
  • tubulin depolymerizing agents;
  • tubulin binding activity;
  • tumor vasculature - potential therapeutic target

Summary

This chapter contains sections titled:

  • Introduction

  • Early history

  • Formulation of the VDA concept

  • Effects of vascular occlusion on tumor cell survival

  • Rational development of VDA therapeutics

  • Development of small-molecule VDAs

  • Combretastatin A4 phosphate

  • The viable rim

  • Conclusions

  • References